$AVXL It is frustrating to see the reversal. The main reason is the lack of straight answers from the management, especially Dr. M, to some simple questions. The tendency to use buzz words instead of direct communication gives investors hesitancy as well. 1, Have Anavex contacted any of the regulatory authorities after P2/3 adult Rett trial? Are there any responses? No straight answers. 2, Did US FDA involve in the change of primary endpoint in the Rett trial? 3, Did PDD trial achieve the primary endpoints initially designed (listed on clinicaltrials.gov/)? The constant delays of everything do not help either. I believe 273 will be a viable drug to treat AD and PD if the managements do not mess it up.